Core Points - The company has established an Audit Committee under the Board of Directors to enhance internal control and governance structure, in accordance with relevant laws and regulations [1][2][3] - The Audit Committee is responsible for reviewing financial information, supervising internal and external audits, and evaluating internal controls [3][4][5] - The committee consists of five members, including three independent directors, with at least one being a professional accountant [2][3][4] Group 1: Audit Committee Structure - The Audit Committee is composed of five directors who are not senior management, including three independent directors [2][3] - The committee is led by a chairperson who is an independent director with accounting expertise [2][3] - The term of the Audit Committee aligns with that of the Board of Directors, and members can be re-elected [2][3] Group 2: Responsibilities and Authority - The Audit Committee is tasked with reviewing financial reports, supervising audits, and ensuring compliance with laws and regulations [3][4][5] - It must approve significant financial disclosures and the hiring or dismissal of external auditors [3][4] - The committee is also responsible for monitoring internal audit activities and ensuring effective internal controls [4][5] Group 3: Operational Procedures - The Audit Committee meets at least quarterly, with additional meetings as needed, and requires a quorum of two-thirds of its members to proceed [6][10] - Meeting notifications must be sent at least two days in advance, and minutes must be recorded and maintained for ten years [10][12] - The committee can invite external experts for professional opinions as necessary [10][12]

关于选举第十一届董事会职工代表董事的公告 特此公告。 健民药业集团股份有限公司 董事会 二〇二五年七月三十一日 证券代码：600976 证券简称：健民集团 公告编号：2025-028 健民药业集团股份有限公司 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述或 者重大遗漏，并对其内容的真实性、准确性和完整性承担个别及连带责任。 根据健民药业集团股份有限公司（以下简称"公司"）2025 年第一次临时股东 大会审议通过的《公司章程（2025 修订稿）》，公司董事会成员中应至少有一名职 工代表，董事会中的职工代表董事由公司职工通过职工代表大会、职工大会、职代 会联席会或者其他形式民主选举产生。 波先生为公司第十一届董事会职工代表董事，任期自会议通过之日起至第十一届董 事会任期届满之日为止。胡振波先生简历详见附件。 胡振波先生与公司持股 5%以上的股东、实际控制人、公司其他董事、高级管理 人员不存在关联关系，未持有公司股票；胡振波先生具备担任公司董事的资格和能 力，不存在《中华人民共和国公司法》《上海证券交易所股票上市规则》《上海证 券交易所上市公司自律监管指引第 1 号——规范运作》和《公司章程》 ...

Core Viewpoint - The announcement details the completion of the board of directors' re-election and the appointment of senior management personnel at Jianmin Pharmaceutical Group Co., Ltd, highlighting the new board composition and management structure [1][2][3]. Board Re-election - The 11th board of directors consists of four non-independent directors: Mr. Wang Siyang, Mr. Yuan Pingdong, Mr. Wang Jun, and Mr. Xu Liang, along with three independent directors: Mr. Guo Yunpei, Mr. Yang Zhi, and Mr. Xin Jinguo, plus employee representative director Mr. Hu Zhenbo, serving a three-year term [1][2]. - Mr. Yuan Pingdong was elected as the chairman of the 11th board of directors [2]. Specialized Committees - The specialized committees of the board were established as follows: - Strategic and Sustainable Development Committee: Members include Yuan Pingdong, Guo Yunpei, Wang Siyang, Wang Jun, and Hu Zhenbo, with Yuan Pingdong as the convener [2]. - Audit Committee: Members include Xin Jinguo, Guo Yunpei, Yang Zhi, Pei Rong, and Xu Liang, with Xin Jinguo as the convener [2]. - Nomination Committee: Members include Guo Yunpei, Yang Zhi, Xin Jinguo, Wang Siyang, and Wang Jun, with Guo Yunpei as the convener [2]. - Compensation and Assessment Committee: Members include Yang Zhi, Guo Yunpei, Xin Jinguo, Yuan Pingdong, and Wang Siyang, with Yang Zhi as the convener [2]. - Independent directors constitute more than half of the audit, nomination, and compensation committees, with Xin Jinguo being a professional accountant [2]. Senior Management Appointments - Mr. Wang Jun was reappointed as the president of the company [2]. - Mr. Huang Zhijun and Mr. Pei Xuejun were reappointed as vice presidents [2]. - Mr. Cheng Chaoyang was reappointed as the financial director [2][3]. - Mr. Zhou Jie was reappointed as the board secretary, and Ms. Cao Hong was reappointed as the securities affairs representative [3]. Cancellation of Supervisory Board - The company will no longer have a supervisory board or supervisors, as approved by the 2025 first extraordinary shareholders' meeting and in accordance with relevant laws and regulations [4].

Core Points - Jianmin Group announced the election of Mr. Hu Zhenbo as the employee representative director of the company's 11th board of directors during a joint meeting of the labor union committee on July 30, 2025 [2] Summary by Category - **Company Announcement** - Jianmin Group held a timely joint meeting of the labor union committee on July 30, 2025 [2] - Mr. Hu Zhenbo was elected as the employee representative director [2]

Core Viewpoint - Jianmin Group announced the continued appointment of Mr. Cheng Zhaoyang as the Chief Financial Officer (CFO) of the company [2] Summary by Categories - **Company Announcement** - Jianmin Group released a notice on July 30, confirming the reappointment of Mr. Cheng Zhaoyang as the CFO [2]

（文章来源：证券日报） 证券日报网讯 7月30日晚间，健民集团发布公告称，公司2025年第一次临时股东大会于2025年7月30日 召开，审议通过了《关于修订及其附件的议案》等多项议案。 ...

证券日报网讯 7月30日晚间，健民集团发布公告称，公司第十一届董事会第一次会议审议通过了《关于 选举公司董事长的议案》等多项议案。 （文章来源：证券日报） ...

Group 1 - The core revenue composition of Jianmin Group for the year 2024 is as follows: pharmaceutical industry accounts for 49.83%, pharmaceutical commerce accounts for 49.56%, and other businesses account for 0.6% [1] Group 2 - Jianmin Group announced that its 11th First Board Meeting will be held on July 30, 2025, in Wuhan, Hubei Province, where the agenda includes the election of the company's chairman [3]

二○二五年七月三十日 健民药业集团股份有限公司 制度文件 健民药业集团股份有限公司 董事会审计委员会实施细则 第一章 总则 第一条 为加强健民药业集团股份有限公司（以下简称：公司）内部控制， 完善公司治理结构，根据《中华人民共和国公司法》《中华人民共和国证券法》 《上市公司治理准则》《上海证券交易所上市公司自律监管指引第 1 号——规范 运作》《健民药业集团股份有限公司章程》（以下简称《公司章程》）及其他有 关规定，结合公司实际情况，公司董事会设立审计委员会，并制定本细则。 第二条 审计委员会是董事会下设的专门委员会，主要负责审核公司财务信 息及其披露、监督及评估内外部审计工作和内部控制，对董事会负责，向董事会 报告工作。 第三条 公司须为审计委员会提供必要的工作条件，配备专门人员或者机构 承担审计委员会的工作联络、会议组织、材料准备和档案管理等日常工作。审计 委员会履行职责时，公司管理层及相关部门须给予配合。 第二章 人员组成 第四条 审计委员会成员由五名不在公司担任高级管理人员的董事组成，其 中独立董事三名，至少有一名独立董事为会计专业人士。 第五条 审计委员会委员由二分之一以上独立董事或者全体董事的三分 ...

健民药业集团股份有限公司 关于选举第十一届董事会职工代表董事的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述或 者重大遗漏，并对其内容的真实性、准确性和完整性承担个别及连带责任。 根据健民药业集团股份有限公司（以下简称"公司"）2025 年第一次临时股东 大会审议通过的《公司章程（2025 修订稿）》，公司董事会成员中应至少有一名职 工代表，董事会中的职工代表董事由公司职工通过职工代表大会、职工大会、职代 会联席会或者其他形式民主选举产生。 2025 年 7 月 30 日，公司工会委员会及时召开了职代会联席会，会议选举胡振 波先生为公司第十一届董事会职工代表董事，任期自会议通过之日起至第十一届董 事会任期届满之日为止。胡振波先生简历详见附件。 胡振波先生与公司持股 5%以上的股东、实际控制人、公司其他董事、高级管理 人员不存在关联关系，未持有公司股票；胡振波先生具备担任公司董事的资格和能 力，不存在《中华人民共和国公司法》《上海证券交易所股票上市规则》《上海证 券交易所上市公司自律监管指引第 1 号——规范运作》和《公司章程》等规定的不 得担任公司董事的情形，也不存在被中国证券监督管 ...